|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
In Gen assets
|
|
gptkbp:awards
|
industry recognition
|
|
gptkbp:biotech_innovation
|
new technologies
|
|
gptkbp:biotech_leadership
|
industry leaders
|
|
gptkbp:biotech_partnerships
|
collaborative ventures
|
|
gptkbp:biotechnology_trends
|
emerging technologies
|
|
gptkbp:business_model
|
gptkb:Ethics
genetic manipulation
|
|
gptkbp:ceo
|
gptkb:Lewis_Dodgson
|
|
gptkbp:clinical_trial
|
ongoing
patient studies
|
|
gptkbp:collaboration
|
gptkb:scientific_community
|
|
gptkbp:collaborations
|
universities
research institutions
|
|
gptkbp:collaborative_projects
|
international research
|
|
gptkbp:community
|
scientific network
|
|
gptkbp:community_engagement
|
local initiatives
|
|
gptkbp:community_outreach
|
gptkb:educational_programs
|
|
gptkbp:competitors
|
gptkb:In_Gen
|
|
gptkbp:conference
|
biotech conferences
|
|
gptkbp:customer_base
|
healthcare providers
|
|
gptkbp:employees
|
500+
|
|
gptkbp:founded
|
gptkb:2022
|
|
gptkbp:founder
|
gptkb:Lewis_Dodgson
|
|
gptkbp:funding
|
grants
|
|
gptkbp:future_goals
|
expand research
|
|
gptkbp:future_prospects
|
next-generation therapies
|
|
gptkbp:global_presence
|
international operations
|
|
gptkbp:grants
|
funding opportunities
|
|
gptkbp:has_advisory_board
|
experts
|
|
gptkbp:has_research_center
|
laboratories
|
|
gptkbp:headquarters
|
gptkb:California
|
|
gptkbp:healthcare
|
medical breakthroughs
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Biosyn Genetics
|
|
gptkbp:impact
|
scientific advancements
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:innovation
|
gptkb:biotechnology
cutting-edge research
|
|
gptkbp:invention
|
patents
genetic modification techniques
|
|
gptkbp:investment
|
gptkb:venture_capital
|
|
gptkbp:investment_focus
|
healthcare
|
|
gptkbp:involved_technology
|
academic partnerships
|
|
gptkbp:location
|
gptkb:San_Diego
|
|
gptkbp:market
|
industry analysis
|
|
gptkbp:market_launch
|
new genetic therapies
|
|
gptkbp:market_position
|
leading biotech firm
|
|
gptkbp:marketing_strategy
|
innovation-driven
|
|
gptkbp:mission
|
advancing genetic research
|
|
gptkbp:notable_project
|
dinosaur cloning
|
|
gptkbp:parent_company
|
gptkb:Biosyn_Corporation
|
|
gptkbp:partnership
|
gptkb:In_Gen
|
|
gptkbp:partnerships
|
pharmaceutical companies
|
|
gptkbp:portfolio_company
|
genetic solutions
|
|
gptkbp:product
|
genetically modified organisms
new therapies
|
|
gptkbp:public_relations
|
media outreach
|
|
gptkbp:publications
|
research papers
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
biotech regulations
|
|
gptkbp:research
|
genetic studies
|
|
gptkbp:research_focus
|
de-extinction
|
|
gptkbp:social_responsibility
|
ethical research practices
|
|
gptkbp:specializes_in
|
genetic engineering
|
|
gptkbp:sustainability_practices
|
green technology
|
|
gptkbp:technology
|
gptkb:CRISPR
|
|
gptkbp:treatment
|
patient results
|
|
gptkbp:vision
|
sustainable biotechnology
|
|
gptkbp:website
|
biosyn.com
|
|
gptkbp:bfsParent
|
gptkb:Dominion_Biosyn_Expansion
|
|
gptkbp:bfsLayer
|
7
|